Caricamento...
Rasagiline, Parkinson neuroprotection, and delayed-start trials: Still no satisfaction?
Rasagiline has been studied as a Parkinson disease (PD) neuroprotective agent in 2 major clinical trials, utilizing the delayed-start design in an attempt to separate symptomatic drug benefits from a disease-modifying effect. The ostensibly positive outcomes of these studies, however, are obscured b...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
American Academy of Neurology
2010
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2865777/ https://ncbi.nlm.nih.gov/pubmed/20368634 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e3181d7d8e2 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|